-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3199 Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup

Program: Oral and Poster Abstracts
Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, epidemiology, Clinical Research, patient-reported outcomes, Diseases, Human
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Humberto Martinez-Cordero, MD, MSc1,2, Camila Peña, MD3, Natalia Paola Schutz, MD4,5,6, Virginia Bove, MD7*, Fiorella Villano, MD8*, Rocío Osorio, MD9*, Mauricio Chandia, MD10*, Cecilia Beltrán, MD11*, Javier Schulz, MD12*, Daniela Cardemil, MD13*, Carolina Contreras, MD14*, Carmen Gloria Vergara, MD14*, Javiera Donoso, MD15*, Marcela Espinoza, MD16*, Gabriel La Rocca, MD17*, Hernán López-Vidal, MD18*, Pilar León, MD19*, Macarena Roa, MD20*, Christine Rojas, MD21*, Pablo Soto, MD22*, Sandra Aranda, MD23*, Vivianne Torres, MD24*, Paola Ochoa, MD25*, Patricio Duarte, MD26,27, Guillermina Remaggi, MD28*, Sebastian Yantorno, MD29*, Ariel Corzo, MD30*, Soledad Zabaljauregui, MD31*, Claudia Shanley, MD32*, Sergio Lopresti33*, Sergio Orlando, MD34*, Veronica Verri, MD35*, Luis Darío Quiroga, MD36*, Juan Jose Garcia, MD37, Vanesa Fernandez, MD38*, Dorotea Fantl, MD39, Jhoanna Ramirez, MD40*, Alicia Molina, MD41*, Pilar Papilco, MD41*, Alex Mite, MD41*, Ines Reyes, MD42, Brenner Sabando Vélez, MD43*, Francisca M. Ramirez Aspiazu, MD44*, Claudia Lucia Sossa45,46*, Virginia Abello, MD46,47,48*, Henry Idrobo, MD46,49*, Domingo Saavedra, MD46,50*, Guillermo Quintero, MD, MBA46,51, Lina Gaviria, MD46,52*, Rigoberto Gomez, MD46,53*, Monica Osuna Pérez, MD46,54*, Alicia Henao-Uribe, MD46,55, Luz del Carmen Tarín Arzaga, MD56*, Omar Cantú-Martínez, MD57*, David Gomez-Almaguer, MD58, Yarely Itzayana García-Navarrete, MD59*, Antonio Cruz-Mora, MD60*, Yahveth Cantero-Fortiz, MD61*, Guillermo J. Ruiz-Arguelles, FRCP62, Eloisa Riva, MD, MEd63 and Isabella Novoa-Caicedo64*

1Instituto Nacional de Cancerologia, Bogota, Bogota, Colombia
2Master program in Epidemiology - Universidad el Bosque, Bogotá, Colombia
3Hematology Department, Hospital Del Salvador, Santiago, Chile
4Hospital Italiano de Buenos Aires, Buenos Aires, BA, Argentina
5Hematology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
6GAMM (Grupo Argentino de Mieloma Múltiple), Buenos Aires, Argentina
7Hospital Central de las FF.AA., Montevideo, Uruguay
8CASMU, Montevideo, Uruguay
9Hospital de Arica, Arica, Chile
10Hospital de Concepcion, Concepción, Chile
11Departamento de Medicina Interna, Universidad de la Frontera, Temuco, Chile
12Hospital de Temuco, Temuco, Chile
13Hospital de Punta Arenas, Punta Arenas, Chile
14Hospital de Rancagua, Rancagua, Chile
15Hospital Sótero del Río, Santiago, Chile
16Hospital San José, Santiago, Chile
17Hospital Regional de Coyhaique, Coyhaique, Chile
18Hospital Barros Luco, Santiago, Chile
19Hospital Van Buren, Valparaiso, Chile
20Hospital Del Salvador, Santiago, Chile
21Hospital Gustavo frieke, Viña Del Mar, Viña Del Mar, CHL
22Hospital Dr. Eduardo Schütz Schroeder, Puerto Montt, Chile
23Hospital San Juan de Dios, Santiago, Chile
24Hospital Base de Valdivia, Valdivia, Chile
25Instituto Alexander Fleming, Buenos aires, Argentina
26CEMIC, Buenos Aires, Argentina
27CEMIC University Hospital, Buenos Aires, Argentina
28Fundaleu, Buenos Aires, Argentina
29Hospital Italiano de la Plata, La Plata, Argentina
30Hospital de Clinicas, Buenos Aires, Argentina
31Academia Nacional de Medicina, Ciudad Autonoma De Buenos Aires, BA, ARG
32Hospital Británico, Buenos Aires, Argentina
33Hospital Nacional Alejandro Posadas, Buenos Aires, Argentina
34Hospital Rossi, La Plata, Argentina
35Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina
36Hospital Churruca, Buenos Aires, Argentina
37Hospital Privado de Cordoba, Cordoba, Argentina
38Hospital Mendez, Buenos Aires, Argentina
39Hospital Italiano de Buenso Aires (HIBA), Buenos Aires, Argentina
40Hospital Teodoro Maldonado, Guayaquil, Ecuador
41HOSPITAL IESS, Guayaquil, Ecuador
42IDYTES, Guayaquil, Ecuador
44HOSPITAL IESS, Guayaquil, Guayas, Ecuador
45Hematology and Hematopoietic Stem Cell Transplantation Unit, Clinica FOSCAL, Floridablanca, Santander, Colombia
46RENEHOC, Bogotá, Colombia
47Servicio de Hematología, Hospital de San José., Bogota, Colombia
48Hospital de San José, Bogota, Colombia
49Facultad de Medicina., Universidad Del Valle, Cali, Colombia
50Clinica Vida, Medellin, Colombia
51Hematology Department, Hospital Universitario Fundación Santa Fe de Bogotá, Bogota, Colombia
52Hospital Universitario San Vicente de Paul, Medellín, Colombia
53Asociación Colombiana de Hematología y Oncología, Cali, Colombia
54Clinica Los Nogales, Bogotá, Colombia
55Clinica De Oncologia Astorga, Medellin, Antioquia, COL
56Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. José Eleuterio Gonzalez", Servicio de Hematología, Monterrey, NL, Mexico
57Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, Mexico
58Servicio de Hematología, Universidad Autónoma de Nuevo León. Facultad de Medicina y Hospital Universitario “Dr. José Eleuterio González”, Monterrey, NL, Mexico
59Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico
60Clínica Ruiz; Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
61Universidad de las Américas Puebla, San Pedro Cholula, Mexico
62Centro De Hematologia Medicina Interna, Puebla, Pue, Mexico
63Cátedra de Hematología, Hospital de Clínicas, Facultad de Medicina, Montevideo, Montevideo, Uruguay
64Facultad de Medicina, Universidad El Bosque, Bogóta, Colombia


Less than 2% of patients with multiple myeloma (MM) are diagnosed 40 or younger, and it has been reported that these patients may have better clinical outcomes. We analyze the clinical behaviour of these young patients in Latin America.


An international multicenter retrospective cohort study comparing the clinical behaviour of patients 40 years or younger with older patients. A total of 1,316 patients receiving treatment for MM between 2010 and 2018 using the IMWG diagnostic criteria were included from 6 Latin American countries. Demographic characteristics, clinical presentation, response to treatment, and overall survival were analyzed.


We included three different cohorts 40 or younger (n=103), 41 to 50 (n=256) and 51 or older (n=957). The median age of the 103 patients aged 40 years or younger was 35.14 years, and 64.1% were men. There were no significant differences in demographics, clinical presentation, treatment received and pre-and post-transplant response rates across the three cohorts Tables 1 to 4. However, there is a trend to deepen post-ASCT response in those under 40. With a median follow-up of 32 months, the median OS for the entire cohort was 85 months, with no statistically significant difference for the three age groups (p=0.337). The median OS for the entire cohort that did not undergo ASCT was 53 months and 93 months in the transplanted group, with no statistically significant differences across the three age groups (p= 0.940) Figure 1. Specifically, in the group aged 40 or younger, 53.4% were transplanted, and the median OS in this group was 78 months and 63 months in the younger non-transplanted group.


Overall, we found that the young Latin-American population has the same clinical presentation and achieves the same responses and survival as older patients. Those young patients may require a different therapeutic approach.

Disclosures: Rojas: AstraZeneca: Other: Personal fees; Roche: Other: Personal fees; Novartis: Other: Personal fees; Janssen: Other: Personal fees. Gomez-Almaguer: Janssen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; BMS: Consultancy, Honoraria.

*signifies non-member of ASH